No Association between Common Chemokine and Chemokine Receptor Gene Variants and Prostate Cancer Risk

Petersen, Desiree C.; Severi, Gianluca; Hoang, Hoa N.; Padilla, Emma J.D.; Southey, Melissa C.; English, Dallas R.; Hopper, John L.; Giles, Graham G.; Hayes, Vanessa M.

doi:10.1158/1055-9965.epi-08-0896

Cited by 14 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Petersen et al . did not identify an association between the SDF-1 rs1801157 polymorphism and prostate cancer susceptibility 15 , and similar negative results were also detected by Tee and colleagues 16 .…”

supporting

confidence: 71%

The SDF-1 rs1801157 Polymorphism is Associated with Cancer Risk: An Update Pooled Analysis and FPRP Test of 17,876 Participants

Xiang

Deng

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The stromal cell derived factor-1 (SDF-1) rs1801157 gene polymorphism has been implicated in susceptibility to cancer, but the results were inconclusive. The current study was to precisely investigate the association between SDF-1 rs1801157 polymorphism and cancer risk using meta-analysis and the false positive report probability (FPRP) test. All 17,876 participants were included in the study. The meta-analysis results indicated a significant association between the SDF-1 rs1801157 polymorphism and cancer risk. By subgroup analyses, the results detected that the SDF-1 rs1801157 polymorphism was associated with cancer susceptibility among Asians and Caucasians. Additionally, we also found significant associations between the SDF-1 rs1801157 polymorphism and susceptibility to different types of cancer. However, to avoid a “false positive report”, we further investigated the significant associations observed in the present meta-analysis using the FPRP test. Interestingly, the results of the FPRP test indicated that only 4 gene models were truly associated with cancer risk, especially in Asians. Moreover, we confirmed that the SDF-1 rs1801157 gene polymorphism was only associated with lung and urologic cancer risk. In summary, this study suggested that the SDF-1 rs1801157 polymorphism may serve as a risk factor for cancer development among Asians, especially an increased risk of urologic and lung cancers.

show abstract

supporting

confidence: 71%

The SDF-1 rs1801157 Polymorphism is Associated with Cancer Risk: An Update Pooled Analysis and FPRP Test of 17,876 Participants

Xiang

Deng

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The authors reported no association of either homozygous or heterozygous CCR5∆32 genotype with prostate cancer development, nor with the clinicopathologic status [190]. Similar results were obtained in an earlier case-control study by Petersen and co-workers [191] in a larger Australian cohort. Blood samples were obtained from participants and subjected to PCR analysis to determine CCR5∆32 genotypes.…”

Section: Cancersupporting

confidence: 77%

“…Similar allelic frequencies were observed among patients and healthy controls. The authors thus concluded CCR5∆32 to not be associated with susceptibility to prostate cancer [191].…”

Section: Cancermentioning

confidence: 96%

Metabolomics as an Approach to Characterise the Contrasting Roles of CCR5 in the Presence and Absence of Disease

Rautenbach

Williams

2020

IJMS

View full text Add to dashboard Cite

Chemokine receptors such as C-C chemokine receptor 5 (CCR5) are activated through interaction with their ligands and are well known for their role in chemotaxis and signal transduction. While serving these roles, cellular responses are effected, hence the immune function of these molecules is established. Given the role of CCR5 in immune function and that the immune and metabolic systems are interlinked, subsequent immune-directed changes should be measurable at a metabolic level. Numerous investigations have reported on metabolic changes associated with CCR5 status in the presence of disease, so as to understand whether specific CCR5 genotypes, frequency and/or levels offer protection to the host or not. However, these metabolic changes were recorded using older conventional techniques. Depending on certain factors such as the disease model, the geography of the samples and/or the ethnic group under study, the role of CCR5 in disease differs. In addition, little is known about CCR5’s role in the absence of an enhanced inflammatory state, such as when infection persists. Metabolomics is defined as the study of metabolites and informs on metabolic changes within living organisms as induced by various stimuli, such as the interaction of CCR5 with its ligand. Since metabolomics reflects the underlying biochemical activity and state of cells/tissues, this review proposes it as a tool to clarify the contrasting roles of CCR5.

show abstract

“…In a study involving 607 Caucasian male residents of Spain (297 cases, 3011 controls), Saenz-Lopez and co-workers (2008) observed a 1.44-fold increase in PCA risk among carriers of the CCL5 rs2107538 GA+AA genotype (P = 0.039) [18]. However, this finding did not corroborate with a larger null report consisting of 1553 Caucasian men (i.e., 815 PCA cases, 738 controls) from Australia [33]. Our findings of a protective effect against PCA among our study participants is consistent with other published reports that reveal a decrease in the risk of developing gastric cancer, lymphoma, and type 1 diabetes [10,16,20].…”

Section: Discussionmentioning

confidence: 98%

Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent:a case-control study

Kidd

Jones

Rogers

et al. 2012

Hered Cancer Clin Pract

View full text Add to dashboard Cite

BackgroundChemokine and chemokine receptors play an essential role in tumorigenesis. Although chemokine-associated single nucleotide polymorphisms (SNPs) are associated with various cancers, their impact on prostate cancer (PCA) among men of African descent is unknown. Consequently, this study evaluated 43 chemokine-associated SNPs in relation to PCA risk. We hypothesized inheritance of variant chemokine-associated alleles may lead to alterations in PCA susceptibility, presumably due to variations in antitumor immune responses.MethodsSequence variants were evaluated in germ-line DNA samples from 814 African-American and Jamaican men (279 PCA cases and 535 controls) using Illumina’s Goldengate genotyping system.ResultsInheritance of CCL5 rs2107538 (AA, GA+AA) and rs3817655 (AA, AG, AG+AA) genotypes were linked with a 34-48% reduction in PCA risk. Additionally, the recessive and dominant models for CCR5 rs1799988 and CCR7 rs3136685 were associated with a 1.52-1.73 fold increase in PCA risk. Upon stratification, only CCL5 rs3817655 and CCR7 rs3136685 remained significant for the Jamaican and U.S. subgroups, respectively.ConclusionsIn summary, CCL5 (rs2107538, rs3817655) and CCR5 (rs1799988) sequence variants significantly modified PCA susceptibility among men of African descent, even after adjusting for age and multiple comparisons. Our findings are only suggestive and require further evaluation and validation in relation to prostate cancer risk and ultimately disease progression, biochemical/disease recurrence and mortality in larger high-risk subgroups. Such efforts will help to identify genetic markers capable of explaining disproportionately high prostate cancer incidence, mortality, and morbidity rates among men of African descent.

show abstract

No Association between Common Chemokine and Chemokine Receptor Gene Variants and Prostate Cancer Risk

Cited by 14 publications

References 17 publications

The SDF-1 rs1801157 Polymorphism is Associated with Cancer Risk: An Update Pooled Analysis and FPRP Test of 17,876 Participants

The SDF-1 rs1801157 Polymorphism is Associated with Cancer Risk: An Update Pooled Analysis and FPRP Test of 17,876 Participants

Metabolomics as an Approach to Characterise the Contrasting Roles of CCR5 in the Presence and Absence of Disease

Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent:a case-control study

Contact Info

Product

Resources

About